Evidence map›Paper›PMID 42130667›Full record

ArticleCVIR oncology2025

Technical and Clinical Outcomes of Embolization of Hypervascular Renal Tumors Using Tantalum-Loaded Obsidio Conformable Embolic (Ta-OCE): a single-center experience.

Sandra Gad, Michael Mohnasky, Zachary Schrank, Bryan Harris, Priya Mody, Alexander Villalobos, Andrew Caddell, Arianna Dezfulian, Nima Kokabi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in CVIR oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sandra GadDivision of Vascular & Interventional Radiology, Department of Radiology, University of North Carolina at Chapel Hill, 101 Manning Drive Chapel Hill, North Carolina, NC 27514, USA.ORCID 0009-0008-5872-2686
Michael MohnaskySchool of Medicine, University of North Carolina at Chapel Hill, North Carolina, USA.
Zachary SchrankSchool of Medicine, University of North Carolina at Chapel Hill, North Carolina, USA.
Bryan HarrisDivision of Vascular & Interventional Radiology, Department of Radiology, University of North Carolina at Chapel Hill, 101 Manning Drive Chapel Hill, North Carolina, NC 27514, USA.
Priya ModyDivision of Vascular & Interventional Radiology, Department of Radiology, University of North Carolina at Chapel Hill, 101 Manning Drive Chapel Hill, North Carolina, NC 27514, USA.
Alexander VillalobosDivision of Vascular & Interventional Radiology, Department of Radiology, University of North Carolina at Chapel Hill, 101 Manning Drive Chapel Hill, North Carolina, NC 27514, USA.
Andrew CaddellSchool of Medicine, University of North Carolina at Chapel Hill, North Carolina, USA.
Arianna DezfulianSchool of Public Health, University of Washington, Seattle, USA.
Nima KokabiDivision of Vascular & Interventional Radiology, Department of Radiology, University of North Carolina at Chapel Hill, 101 Manning Drive Chapel Hill, North Carolina, NC 27514, USA.

Funding

UNC Integrated Translational Oncology Program (UNC-iTOP)T32CA244125 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI WILLIAM Y. KIM, Jen Jen Yeh · 2019 to 2026
$3.9M
NCI NIH HHS T32 CA244125
6 · The paper itself

Abstract

Purpose: To evaluate the efficacy and safety of renal artery embolization (RAE) in hypervascular renal tumors using Tantalum-Loaded Obsidio Methods: A single-center institutional review board (IRB) approved retrospective analysis of consecutive patients with benign and malignant hypervascular renal tumors treated with Ta-OCE between May 2023 and June 2024 was performed. Specific clinical data on tumor size reduction, renal function preservation, bleeding, and complications were collected. Follow-up imaging was conducted using MRI or CT scans. Adverse events were evaluated according to the Common Toxicity Criteria for Adverse Events (v.5). Student's t-test was used to compare continuous variables. Results: Overall, Conclusion: Embolization of hypervascular renal tumors with Ta-OCE appears to be safe and effective. Prospective, ideally multicenter studies are needed to further clarify the ideal scenarios for the use of Ta-OCE in hypervascular renal tumors.

Indexed as

AngiomyolipomaConformable EmbolicRenal Artery EmbolizationRenal Cell Carcinoma

Identifiers

PMID42130667
PMCPMC13166167

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.